1.19
Schlusskurs vom Vortag:
$1.12
Offen:
$1.2
24-Stunden-Volumen:
284.89K
Relative Volume:
0.06
Marktkapitalisierung:
$7.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+3.07%
1M Leistung:
-2.08%
6M Leistung:
-98.77%
1J Leistung:
+0.00%
Polyrizon Ltd Stock (PLRZ) Company Profile
Vergleichen Sie PLRZ mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PLRZ
Polyrizon Ltd
|
1.20 | 6.71M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.13 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
Will Polyrizon Ltd. stock keep outperforming rivals2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
How to integrate Polyrizon Ltd. into portfolio analysis toolsQuarterly Trade Summary & Fast Moving Stock Watchlists - newser.com
Is Polyrizon Ltd. stock affected by interest rate hikesDip Buying & Verified Momentum Stock Watchlist - newser.com
What data driven models say about Polyrizon Ltd.’s futureStock Surge & Real-Time Market Sentiment Alerts - newser.com
Applying chart zones and confluence areas to Polyrizon Ltd.2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - newser.com
Analyzing Polyrizon Ltd. with multi timeframe chartsBull Run & Weekly High Potential Stock Alerts - newser.com
How Polyrizon Ltd. stock compares to growth peersWall Street Watch & Verified Momentum Watchlists - newser.com
Applying big data sentiment scoring on Polyrizon Ltd.2025 Retail Activity & Free Real-Time Market Sentiment Alerts - newser.com
Polyrizon Reports Positive Pre-Clinical Results for PL-14 Allergy Blocker - TipRanks
Published on: 2025-10-06 07:52:02 - newser.com
Polyrizon shares preclinical results for nasal allergy blocker - Investing.com
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy - The Manila Times
Polyrizon shares preclinical results for nasal allergy blocker By Investing.com - Investing.com Australia
Leading vs lagging indicators on Polyrizon Ltd. performanceJuly 2025 PostEarnings & Short-Term Swing Trade Alerts - newser.com
1.07% allergen penetration at 1hr — Polyrizon PL-14 forms effective nasal barrier in preclinical study - Stock Titan
Is Polyrizon Ltd. building a consolidation baseQuarterly Profit Review & Fast Exit and Entry Strategy Plans - newser.com
Applying sector rotation models to Polyrizon Ltd.Insider Buying & Comprehensive Market Scan Insights - newser.com
Can technical indicators confirm Polyrizon Ltd.’s reversalPortfolio Performance Summary & Fast Entry High Yield Tips - newser.com
Smart tools for monitoring Polyrizon Ltd.’s price actionMarket Sentiment Report & Growth Focused Stock Reports - newser.com
How strong is Polyrizon Ltd. stock balance sheetPortfolio Update Summary & Weekly High Return Stock Opportunities - newser.com
How moving averages guide Polyrizon Ltd. tradingShare Buyback & Growth Focused Stock Reports - newser.com
What machine learning models say about Polyrizon Ltd.July 2025 EndofMonth & Safe Entry Trade Reports - newser.com
Visualizing Polyrizon Ltd. stock with heatmapsJuly 2025 Action & Daily Profit Focused Stock Screening - newser.com
Is Polyrizon Ltd. stock reversal real or fakeTreasury Yields & AI Powered Market Entry Ideas - newser.com
Published on: 2025-10-03 03:17:45 - newser.com
Finanzdaten der Polyrizon Ltd-Aktie (PLRZ)
Es liegen keine Finanzdaten für Polyrizon Ltd (PLRZ) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):